Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
ODDITY TECH 0CDI.PA-O 0META 11.03MNT.TO 0.69COPX 1.79U.U.TO 0.5SII.TO 2.94IPCO.TO -0.43
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

28.57
+0.60 (2.15%)
as of Aug 25, 2026, 8:00:00 pm Market Open.
582 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 25, 2026, 12:00 am

This summary was created by AI, based on 24 opinions in the last 12 months.

Pfizer Inc. (PFE) has faced challenges following its prominent role during the Covid-19 pandemic, with many experts pointing out the looming patent cliffs and the need for new blockbuster drugs to sustain growth. The company is heavily reliant on its dividends, offering yields between 6% to 8%, which many investors find attractive in a low growth environment. While some view it as a value play due to its low price-to-earnings ratio, others express concerns that it may be a value trap due to uncertain growth prospects. The overall sentiment reflects a cautious approach, favoring the dividend payout amidst worries about drug pipeline sustainability and the impact of recent acquisitions on its future performance.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
BUY

Pfizer Inc(PFE)

Apr 06, 2011
Likes this one especially because they have announced they are going to downsize the company and shareholders will be rewarded for that. Selling a capsule manufacturing company for $2.5 billion.
Photo of Norman LevineNorman LevineUnlock Rating
$20.29

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Mar 25, 2011
Drug sector is all suffering from same thing – drugs coming off patent faster than entering the pipeline. Are trying to rebuild themselves. They are all trying to get their costs down.
Photo of Lorne SteinbergLorne SteinbergUnlock Rating
$20.35

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 24, 2011
Thinks it is turning around. Very good yield. Have a difficult time with some of the blockbuster drugs coming off patent.
Photo of Paul Harris, CFAPaul Harris, CFAUnlock Rating
$20.30

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Mar 15, 2011
Are breaking themselves up after a string of acquisitions. He sees this happening. Want to get rid of their generics.
Photo of Don ReedDon ReedUnlock Rating
$19.76

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Feb 28, 2011
New CEO is changing the company compared to the other pharmas. R&D has been a big pit for all companies and he is cutting this back. Will be basically be cutting the company into smaller parts.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$19.24

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Feb 11, 2011
Not keen on the big pharma complex at this stage. This one in particular has had struggles with their pipeline. There are better ways to play the health care space.
Photo of Karl BergerKarl BergerUnlock Rating
$18.83

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Jan 05, 2011
(A Top Pick Feb 3/10. Down 0.29%.) Model price is $29.91, an upside of 62%. Good dividend. His earnings estimate shows $2.22. Still a Buy.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$18.11

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Dec 23, 2010
A lot of the pharmaceuticals have been in the doldrums for a long time. Large dividend yield and cheap on a PE basis but their large blockbuster drugs are coming off patent.
Photo of Paul Harris, CFAPaul Harris, CFA
No
Unlock Rating
$17.61

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Pfizer Inc(PFE)

Dec 22, 2010
Coming out of the recession pharmaceuticals have not recovered to 2007 levels. Market worries about Obamacare and generics impact on branded drugs. Also worried about FDA approval process.. Also subject to litigation. Tremendous amount of cash and trading at very low multiples. Looking at this.
Photo of David BaskinDavid Baskin
No
Unlock Rating
$17.56

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Dec 17, 2010
Have had a lot of issues and the CEO has left. Has been an abysmal investment over the last 5-10 years. Decent dividend. What do they do when Lipitor goes off patent mid 2011? Their acquisition of Wyeth gives them a decent stream of products. Trading at 8X earnings. Everybody hates it so maybe it’s worth looking at.
Photo of Gavin GrahamGavin GrahamUnlock Rating
$17.03

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Dec 16, 2010
Looked at it a couple of times. Lots of cash, good name, but he has never been able to pull the trigger. He thinks you need to let it go up a bit and increase volume, but if you own it, you get paid to wait.
Photo of Rick StuchberryRick StuchberryUnlock Rating
$17.22

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Nov 19, 2010
Concerned with risk from generic competition to the big pharmas. Prefers Teva (TEVA-Q). The big pharmas will continue to struggle because of this.
Photo of Karl BergerKarl Berger
No
Unlock Rating
$16.80

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Nov 10, 2010
Lost its ability to grow because of its size. Lipitor represents 20% and it goes off patent next year so they’ll be competing with generics.
Photo of Gordon ReidGordon ReidUnlock Rating
$16.83

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Nov 09, 2010
(Top Pick Nov 16/09, Down 5%) Drug stocks have been out of favour. Drug stocks bottomed earlier this year. Have a number of drugs coming off patent. Dividend investors have identified drug companies as targets.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$16.83

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Nov 08, 2010
(Top Pick Nov 30/09, Down 4.77%) $28.23 model price. 64% upside. He keeps on buying it. Held for 4 years in his fund. There is value there and major consolidation going on there. It’s a changing landscape – they are getting together with generics.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$17.05

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
Showing 436 to 450 of 887 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

ATD.TO -0.8$85.19
1523.HK 0$
CSU.TO -20.01$3078.66
NVO 1.74$48.66
PAYC 2.08$231.7
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

ODDITY T… 0$
CDI.PA-O 0$
META 11.03$570.05
MNT.TO 0.69$69.95
COPX 1.79$96.32

Popular Articles

Latest Sell Signals

ORCL 2.31$144.76
GAW-LSE 0$
BB.TO 0.17$10.79
SHOP.TO 5.21$212.84
IBM 3.15$234.19

Most Recent Experts

Jason Del Vicario

Jason Del Vicario

HollisWealth

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Rick Rule

Rick Rule

Rule Investment Media

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like